Mark Jeffrey DeLong is President & VP at Apellis Pharmaceuticals, Inc. (APLS). They have made 27 open-market trades across 1 company since 2021, most recently 2026-05-14.
CIK 0001856078
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 27 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APLS | 41,250 | $1.7M |
Shares reported on the most recent Form 4, priced at the 2026-05-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APLS | SELL | 2026-02-11 | 2026-02-13 | $22.15 | $8K | -0.2% | -12.9% | N/A |
| APLS | SELL | 2026-01-22 | 2026-01-23 | $21.77 | $73K | +7.2% | +4.1% | +89.6% |
| APLS | SELL | 2026-01-20 | 2026-01-21 | $19.79 | $26K | +9.0% | +6.3% | +95.4% |
| APLS | SELL | 2026-01-13 | 2026-01-15 | $22.19 | $39K | +12.4% | +5.1% | +99.0% |
| APLS | SELL | 2025-02-11 | 2025-02-12 | $28.54 | $10K | -6.2% | -14.0% | -39.7% |
| APLS | SELL | 2025-01-29 | 2025-01-30 | $29.52 | $11K | -5.8% | -20.6% | -36.6% |
| APLS | SELL | 2025-01-22 | 2025-01-23 | $30.43 | $42K | -6.4% | -10.8% | -43.1% |
| APLS | SELL | 2025-01-17 | 2025-01-21 | $29.96 | $37K | -3.4% | -5.6% | -39.9% |
| APLS | SELL | 2025-01-13 | 2025-01-14 | $28.70 | $46K | +5.2% | -3.1% | -31.8% |
| APLS | SELL | 2024-03-18 | 2024-03-19 | $56.90 | $1.1M | +6.0% | -15.7% | -28.4% |
| APLS | SELL | 2024-02-12 | 2024-02-13 | $67.77 | $40K | +7.0% | -15.8% | -35.8% |
| APLS | SELL | 2024-01-29 | 2024-01-31 | $64.14 | $24K | +6.8% | +0.7% | -30.4% |
| APLS | SELL | 2024-01-22 | 2024-01-23 | $65.00 | $90K | -6.3% | +1.3% | -28.6% |
| APLS | SELL | 2024-01-16 | 2024-01-17 | $66.81 | $218K | -1.8% | +3.3% | -22.2% |
| APLS | SELL | 2023-10-23 | 2023-10-24 | $46.04 | $6K | -2.5% | +0.8% | +36.3% |
| APLS | SELL | 2022-08-17 | 2022-08-18 | $69.50 | $348K | -9.9% | -2.3% | -33.0% |
| APLS | SELL | 2022-08-11 | 2022-08-12 | $67.00 | $335K | -9.1% | +0.1% | -32.9% |
| APLS | SELL | 2022-08-08 | 2022-08-09 | $64.50 | $323K | +0.4% | +5.9% | -26.4% |
| APLS | SELL | 2022-08-04 | 2022-08-08 | $60.75 | $608K | +3.2% | +1.3% | -24.9% |
| APLS | SELL | 2022-07-27 | 2022-07-28 | $57.00 | $285K | +12.8% | +1.9% | +2.5% |
| APLS | SELL | 2022-07-19 | 2022-07-21 | $56.42 | $282K | +4.7% | +22.4% | +7.4% |
| APLS | SELL | 2022-06-16 | 2022-06-21 | $41.79 | $418K | +6.6% | +23.4% | +49.7% |
| APLS | SELL | 2022-04-20 | 2022-04-22 | $52.53 | $368K | -4.3% | -7.4% | +9.6% |
| APLS | SELL | 2021-07-21 | 2021-07-22 | $65.00 | $65K | -3.3% | -6.0% | -51.3% |
| APLS | SELL | 2021-07-15 | 2021-07-16 | $62.30 | $62K | +11.8% | -7.2% | -41.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.